openPR Logo
Press release

ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

07-02-2024 09:00 PM CET | Health & Medicine

Press release from: ABNewswire

ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials,

DelveInsight's, "ANCA Vasculitis Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in ANCA Vasculitis Research. Learn more about our innovative pipeline today! @ ANCA Vasculitis Pipeline Outlook [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the ANCA Vasculitis Pipeline Report

* June 2024:- Amgen- A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
* June 2024:- Alpine Immune Sciences Inc.- An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3). The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases.
* DelveInsight's ANCA Vasculitis pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for ANCA Vasculitis treatment.
* The leading ANCA Vasculitis Companies such as Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
* Promising ANCA Vasculitis Therapies such as BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.

Stay informed about the cutting-edge advancements in ANCA Vasculitis Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases care @ ANCA Vasculitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ANCA Vasculitis Emerging Drugs Profile

* Abatacept: Bristol-Myers Squibb

Abatacept is a selective T-cell co-stimulation modulator. Abatacept binds to CD80 and CD86 receptors on antigen-presenting cells (APCs), which are essential for T-cell activation. This binding blocks the interaction between CD80/CD86 and CD28, thereby inhibiting the delivery of the second co-stimulatory signal required for optimal T-cell activation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ANCA Vasculitis.

* Sparsentan : Travere Therapeutics

Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

Learn more about ANCA Vasculitis Drugs opportunities in our groundbreaking ANCA Vasculitis Research and development projects @ ANCA Vasculitis Unmet Needs [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

ANCA Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

ANCA Vasculitis Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Discover the latest advancements in ANCA Vasculitis Treatment by visiting our website. Stay informed about how we're transforming the future of cardiovascular disease @ ANCA Vasculitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the ANCA Vasculitis Pipeline Report

* Coverage- Global
* ANCA Vasculitis Companies- Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
* ANCA Vasculitis Therapies- BDB-001 injection, Cyclophosphamide, Glucocorticoids, Avacopan, Iptacopan, NM8074, and others.
* ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of ANCA Vasculitis Pipeline on our website @ ANCA Vasculitis Drugs and Companies [https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* ANCA Vasculitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* ANCA Vasculitis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Abatacept: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Sparsentan: Travere Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* ANCA Vasculitis Key Companies
* ANCA Vasculitis Key Products
* ANCA Vasculitis- Unmet Needs
* ANCA Vasculitis- Market Drivers and Barriers
* ANCA Vasculitis- Future Perspectives and Conclusion
* ANCA Vasculitis Analyst Views
* ANCA Vasculitis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anca-vasculitis-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ANCA Vasculitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here

News-ID: 3562570 • Views:

More Releases from ABNewswire

Tokyo Portfolio Launches Tokyo's #1 Real Estate Platform for Global Buyers
Tokyo Portfolio Launches Tokyo's #1 Real Estate Platform for Global Buyers
150K+ social subscribers, 12M+ views, and 200K+ monthly pageviews power Tokyo's leading English portal for highend homes Tokyo, Japan - August 29, 2025 - Tokyo Portfolio announced today that it has become Japan's mostwatched Englishlanguage brand focused on real estate, combining a large global audience with a highperforming listings portal for luxury rentals and purchases in Tokyo. The brand's videos and guides help expats and international buyers navigate one of the
Floor Boys Introduces Premium Pet-Friendly Flooring Solutions for South Carolina Homeowners
Floor Boys Introduces Premium Pet-Friendly Flooring Solutions for South Carolina …
Lexington-Based Flooring Specialist Offers Scratch-Resistant, Easy-Clean Flooring Options Perfect for Pet Owners LEXINGTON, SC - Floor Boys Flooring Professionals, backed by 125+ years of combined experience serving Lexington and surrounding South Carolina communities, announces its expanded focus on pet-friendly flooring solutions designed specifically for homeowners with dogs, cats, and other pets. The company specializes in scratch-resistant luxury vinyl plank (LVP), waterproof carpet, tile, and hardwood alternatives that combine durability with style
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more. It is now a lifestyle choice. Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better. In areas with seasonal weather, where people can be outside for most of the year, homeowners
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecedented Demand from Motor City Small Business Owners
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape. The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative

All 5 Releases


More Releases for ANCA

ANCA Vasculitis Market to Rise by 2032 | AstraZeneca, GlaxoSmithKline, Travere T …
DelveInsight's "ANCA Vasculitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of ANCA Vasculitis, historical and forecasted epidemiology as well as the ANCA Vasculitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The ANCA Vasculitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted ANCA Vasculitis market size
ANCA Vasculitis Clinical Trials, Pipeline Insights, Treatment Drugs, and Compani …
DelveInsight's, "ANCA Vasculitis Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in ANCA Vasculitis
ANCA Vasculitis Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "ANCA Vasculitis Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in ANCA Vasculitis
ANCA Vasculitis Market to Reach US$ 534.3 Million by 2034
Market Overview: The ANCA vasculitis market reached a value of US$ 339.0 Million in 2023 and expected to reach US$ 534.3 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034. The report offers a comprehensive analysis of the ANCA vasculitis market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market,
MaxWeb Celebrates Success as Affiliate Insider by Anca Gita Tops Bestseller Char …
[Baia Mare, April 10, 2024] - MaxWeb, a leading affiliate marketing network, is thrilled to announce the outstanding success of "Affiliate Insider" by Anca Gita, which has soared to the top of the charts on its release. The book has achieved the remarkable feat of hitting #1 and #2 on the Top New Releases and #3 on the International Best Seller list on Kindle Direct Publishing (KDP). "Affiliate Insider" provides invaluable
ANCA Vasculitis Market to Reach US$ 534.3 Million by 2034
Market Overview: The ANCA vasculitis market reached a value of US$ 339.0 Million in 2023 and expected to reach US$ 534.3 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034. The report offers a comprehensive analysis of the ANCA vasculitis market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market,